ArticleFrontiers in veterinary science2020
Protection of Cattle Elicited Using a Bivalent Lumpy Skin Disease Virus-Vectored Recombinant Rift Valley Fever Vaccine.
Article in Frontiers in veterinary science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- The global scenario of lumpy skin disease, its epidemiological investigation, and prevalence in livestock: A review.Veterinary and animal science · 2026Review
- Diagnostic approach, vaccination and treatment priorities for Lumpy Skin Disease in cattle: lessons from Balkan epidemics to Western Europe re-emergence (2025).Veterinary research communications · 2026Review
- A One Health approach to bovine coronavirus vaccine development, using LSDV as a live virus vector.Human vaccines & immunotherapeutics · 2025Article
- Assessment of Biological Properties of Recombinant Lumpy Skin Disease Viruses with Deletions of Immunomodulatory Genes.Viruses · 2025Article
- Article
- Has the epidemiologic conundrum of Rift Valley fever changed?Tropical animal health and production · 2025Review
- Progress in diagnostic methods and vaccines for lumpy skin disease virus: a path towards understanding the disease.Veterinary research communications · 2025Review
- Article
- Article
- Article
- Production of recombinant lumpy skin disease virus A27L and L1R proteins for application in diagnostics and vaccine development.Vaccine: X · 2023Article
- Safety and immunogenicity of inactivated Rift Valley Fever Smithburn viral vaccine in sheep.Virology journal · 2023Article
- Review
- Development of a dual vaccine against East Coast fever and lumpy skin disease.Frontiers in immunology · 2023Article
- Improved safety profile of inactivated Neethling strain of the Lumpy Skin Disease Vaccine.Vaccine: X · 2022Article
- Article
- Review
- Cloning Strategies for the Generation of Recombinant Capripoxvirus Through the Use of Screening and Selection Markers.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Capripoxviruses, leporipoxviruses, and orthopoxviruses: Occurrences of recombination.Frontiers in microbiology · 2022Review
- Bacterium-Like Particles Displaying the Rift Valley Fever Virus Gn Head Protein Induces Efficacious Immune Responses in Immunized Mice.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lumpy skin disease and Rift Valley fever are two high-priority livestock diseases which have the potential to spread into previously free regions through animal movement and/or vectors, as well as intentional release by bioterrorists. Since the distribution range of both diseases is similar in Africa, it makes sense to use a bivalent vaccine to control them. This may lead to the more consistent and sustainable use of vaccination against Rift Valley fever through a more cost-effective vaccine. In this study, a recombinant lumpy skin disease virus was constructed in which the thymidine kinase gene was used as the insertion site for the Gn and Gc protective glycoprotein genes of Rift Valley fever virus using homologous recombination. Selection markers, the enhanced green fluorescent protein and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.